The severe acute respiratory syndrome coronavirus 2 has been a shocking disaster for healthcare systems worldwide since December 2019. This virus can affect all systems of the body and its symptoms vary from a simple upper respiratory infection to fatal complications including end-organ damage. On the other hand, the normal immune system plays a pivotal role in the recovery of infectious diseases such as COVID-19. However, occasionally, exaggerated immune system inflammation and an excessive synthesis of cytokines, known as a "cytokine storm," can deteriorate the patient's clinical condition. Secondary bacterial co-infection is another problem in COVID-19 which affects the prognosis of patients. Although there are a few studies about this complication, they suggest not using antibiotics commonly, especially broad-spectrum ones. During this pandemic, various approaches and therapeutics were introduced for treating COVID-19 patients. However, available treatments are not helpful enough, especially for complicated cases. Hence, in this era, cell therapy and regenerative medicine will create new opportunities. Therefore, the therapeutic benefits of mesenchymal stem cells, especially their antimicrobial activity, will help us understand how to treat COVID-19. Herein, mesenchymal stem cells may stop the immune system from becoming overactive in COVID-19 patients. On the other side, the stem cells' capacity for repair could encourage natural healing processes.

No abstract

Introduction: Many studies have reported the role of vitamin D in rheumatoid arthritis (RA) which is related to several serum autoantibodies such as RF and Anti CCP. It also has been shown that vitamin D deficiency affect the DAS28 and VAS score inversely. Therefore, we aim to assess the relationship between vitamin D deficiency and RA-related autoantibodies including Anti CCP and RF levels and also evaluate the association between these parameters and the severity of disease.Methods: In this cross-sectional study, RA patients over 16 years of age were enrolled. The severity of diseases was assessed via the DAS28 scoring system. Serum levels of 25(OH) vitamin D were determined by the ELISA method, along with other rheumatoid related laboratory evaluations including Anti CCP, RF and CRPResults: A total of 100 patients with a mean age of 45.27± 14.14 were included and evaluated; of them, 75% were female and 77% lived in the city. Most of the patients (66%) had moderate DAS28 levels; however, no substantial relationship was observed between DAS28 and vitamin D levels. A significant positive relation between serum 25(OH)D level and disease duration, as well as the level of education, was observed. There was also no significant correlation between RA-related autoantibodies and inflammatory serum marker with 25(OH)D.Conclusion: Due to vitamin deficiency in the majority of cases (73%) and the relationship between serum 25(OH)D levels and the duration of disease, it can be concluded that vitamin D levels should be checked in those patients.

No abstract

Background Acute lymphoblastic leukemia (ALL) is a malignancy that leads to altered blast cell proliferation, survival, and maturation and eventually to the lethal accumulation of leukemic cells. Recently, dysregulated expression of various micro-RNAs (miRNAs) has been reported in hematologic malignancies, especially ALL. Cytomegalovirus infection can induce ALL in otherwise healthy individuals, so a more detailed evaluation of its role in ALL-endemic areas like Iran is required. Methods In this cross-sectional study, 70 newly diagnosed adults with ALL were recruited. The expression level of microRNA-155(miR-155) and microRNA-92(miR-92) was evaluated by real-time SYBR Green PCR. The correlations between the miRNAs mentioned above and the severity of disease, CMV infection, and acute graft vs. host disease after hematopoietic stem cell transplantation (HSCT) were assessed. B cell and T cell ALL distinction in the level of miRNAs was provided. Results After the statistical analysis, our results indicated a marked increase in the expression of miR-155 and miR-92 in ALL patients vs. healthy controls (*P = 0.002–*P = 0.03, respectively). Also, it was shown that the expression of miR-155 and miR-92 was higher in T cell ALL compared to B cell ALL (P = 0.01–P = 0.004, respectively), CMV seropositivity, and aGVHD. Conclusion Our study suggests that the plasma signature of microRNA expression may act as a powerful marker for diagnosis and prognosis, providing knowledge outside cytogenetics. Elevation of miR-155 in plasma can be a beneficial therapeutic target for ALL patients, with consideration of higher plasma levels of miR-92 and miR-155 in CMV + and post-HSCT aGVHD patients.